

On-line Table 1: Individual patient and ISCM characteristics

Patient	Age	Sex	Primary Neoplasm	Days PET-MRI ^a	ISCM on Clinical PET		MRI		PET	SUVmax	
					Report	ISCM on Review	Location	Size, mm	Location	ISCM	Mediastinum
1	64	F	Melanoma	-21	No	No	C7-T1	10			
2	57	F	Melanoma	-49	No	Yes	L1-4	114	T12/L1-L3/4	5.4	1.8
3	69	M	Melanoma	-7	No	No	T7	5			
4	55	M	Melanoma	0	No	Yes	T12-L1	21	T12-L1	9.0	1.8
5	73	M	Non-small cell lung	-5	Yes	Yes	C2	11	C1-2	9.9	1.8
					Yes	Yes	T4	11	T4	9.8	1.8
					Yes	Yes	T4-5	17	T5	7.5	1.8
					Yes	Yes	T11	18	T10	5.3	1.8
6	75	F	Non-small cell lung	-7	No	No	T8	3			
7	37	F	Melanoma	0	Yes	Yes	C3-4	12	C3-4	7.7	2.3
8	69	F	Non-small cell lung	13	Equivocal	Yes	C1-5	58	C2-3	5.1	2.6
9	54	F	Non-small cell lung	-1	No	Yes	C3	7	C3-4	3.3	1.7
10	55	M	Small-cell lung	7	No	Yes	T9-11	52	T10-11	4.4	2.5

^a PET exams performed before MRI are indicated with -.

On-line Table 2: Group patient and ISCM characteristics

	All Patients (n = 10 Patients, 13 ISCMs)	ISCM Visible on PET Review (n = 7 Patients, 10 ISCMs)	ISCM Not Visible on PET Review (n = 3 Patients, 3 ISCMs)	P Value: ISCM Visibility on PET
Days between PET and MRI, mean, range; -PET before +PET after	11, -49 to +13	11, -49 to +13	12, -21 to -7	.7
Length of CE ISCM on MRI, mm; mean, range	26.1, 3-114	32.1, 7-114	6.0, 3-10	.038
Length of CE ISCM on MRI, No. of segments; mean, range	1.5, 1-4	1.6, 1-4	1.0, 1-1	.11
Length of T2 signal abnormality on MRI, No. of segments; mean, range	4.5, 1-13	5.6, 2-13	1.0, 1-1	.0081
Ratio: segment length T2 signal abnormality to CE, mean, range	3.2, 1-10	3.8, 1-10	1.0, 1-1	.0069
Length of ISCM on PET, No. of segments; mean, range	-	1.3, 1-3	-	
Morphology of PET uptake				
Fusiform, n (%)	-	2/10 (20%)	-	
Round, n (%)	-	8/10 (80%)	-	
SUVmax ISCM, mean, range	-	6.7, 3.3-9.9	-	
Clinical PET report diagnosed ISCM? n (%)				
No, n (%)	7/13 (53.8%)	4/10 (40%)	-	
Yes, n (%)	5/13 (38.5%)	5/10 (50%)	-	
Equivocal, n (%)	1/13 (7.7%)	1/10 (10%)	-	
Primary neoplasm on PET report, n (%)	4/10 (40%)	3/7 (42.8%)	1/3 (33.3%)	
Other metastases on PET report, n (%)	9/10 (90%)	6/7 (85.7%)	3/3 (100%)	
Non-CNS, nonspine metastases on PET report, n (%)	7/10 (70%)	4/7 (57.1%)	3/3 (100%)	
Other CNS metastases on PET report, n (%)	2/10 (20%)	2/7 (28.6%)	0/3 (0%)	
Spinal column skeletal metastases on PET report, n (%)	1/10 (10%)	1/7 (14.3%)	0/3 (0%)	

Note:—CE indicates contrast enhancing.